Andreas Zeiher, MD

Andreas Zeiher, MD

Chairman of Medicine
Department of Cardiology, Angiology, and Nephrology
J. W. Goethe University
Frankfurt, Germany

Related Videos

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions? Video

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk? Video

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients? Video

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab? Video

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

In the interventional cardiology setting, what percentage of your patients do not achieve the ESC Lipid Guideline goal of 70 mg/dL and, therefore, are suitable candidates for PCSK9 inhibition? Can you discuss your patient selection process? Video

In the interventional cardiology setting, what percentage of your patients do not achieve the ESC Lipid Guideline goal of 70 mg/dL and, therefore, are suitable candidates for PCSK9 inhibition? Can you discuss your patient selection process?

From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level <50 mg/dL with a PCSK9 inhibitor? Video

From an IC perspective, in a patient who is post-PCI/post-stent insertion for ACS, when is the aggregated risk of the patient sufficiently alarming for you to consider intensive lowering of LDL-C to a level <50 mg/dL with a PCSK9 inhibitor?